Quick Answer
Compass Therapeutics, Inc. reported Operating Income Loss of -$72.84 million for the year ending 2025.
- Compass Therapeutics, Inc. showed a decrease of -28.6% in Operating Income Loss from 2024 to 2025.
- This data is from Compass Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2018 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2018 to 2025), Compass Therapeutics, Inc.'s Operating Income Loss has declined by 208,011.4%.
- Historical annual values: Fiscal year 2025: -$72.84 million | Fiscal year 2024: -$56.63 million | Fiscal year 2023: -$50.36 million | Fiscal year 2022: -$41.66 million | Fiscal year 2021: -$81.88 million | Fiscal year 2020: -$27.81 million | Fiscal year 2020: -$32.1 thousand | Fiscal year 2019: -$34.05 million | Fiscal year 2019: -$32.8 thousand | Fiscal year 2018: -$35.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: